Bottom line. Centene’s second quarter materially de-risked 2026. Adjusted EPS of $2.51 was more than double the $1.09 pre-print consensus, and the result still would have been approximately $2.01 after removing the roughly $0.50 of 2025 settlements that management does not expect to recur in 2027. That normalized figure beat consensus by 84%. Management also raised the full-year adjusted EPS floor to greater than $4.80 from greater than $3.40. The quarter was therefore much better than a one-time-assisted headline beat, and the risk of another major 2026 reset has fallen substantially.
It did not settle the longer-term debate. Marketplace, Medicare and expense execution produced most of the upside, while Medicaid performed to plan without improving its full-year HBR outlook. That distinction matters after CNC shares rose 47.3% from April 27 through July 27, well ahead of the S&P 500 and XLV. Investors were already paying for a 2026 repair. The question now is whether recurring earnings can grow into 2027 without a faster Medicaid turn.
The beat was real and 2026 is largely settled
The headline revenue beat was less impressive than the earnings result. Total revenue of $53.6B exceeded consensus by $5.9B, but $4.9B, or 83%, of that surprise was premium-tax pass-through. Premium and service revenue of $44.4B still beat the $43.3B hurdle by $1.1B. More importantly, the operating ratios easily cleared the consensus hurdle: HBR of 89.6% was 160 basis points better than consensus, and adjusted SG&A of 6.9% was 30 basis points better.
The new guidance puts much firmer bounds around 2026, but it does not establish a normal earnings base for 2027+. The HBR range improved 40 basis points at the midpoint to 90.5%–91.3%, while the adjusted SG&A range improved 10 basis points to 6.9%–7.5%. Subtracting the $0.50 settlement benefit leaves a simple normalized EPS floor of greater than approximately $4.30, still 22% above the $3.52 consensus entering the report. First-half adjusted EPS was $5.88, but management expects only a little above breakeven in the third quarter and a fourth-quarter loss because of PDP and Commercial seasonality. The first half is not a run rate.
Sources: Centene; StreetAccount; Koyfin; Graver Research calculations.
Commercial and Medicare drove the reset
Marketplace was the largest source of improvement. Commercial HBR fell to 79.2% in 2Q26 from 90.6% in 2Q25. Separately, management raised its FY26 Marketplace pretax-margin outlook to 4.5%–5.0% from the 3% view provided after 1Q26. Approximately $180 million of final 2025 risk-adjustment favorability contributed about 60 basis points of full-year margin, but it did not explain all of the increase. June Wakely claims data supported management’s view of relative acuity, while medical cost developed better than the conservative assumptions adopted after 1Q. The remaining caution is that 2026 risk adjustment is still an estimate and Marketplace membership has continued to decline.
Medicare and SG&A made the reset broader. Medicare HBR improved to 89.5% in 2Q26 from 90.9% in 2Q25; PDP margin is now expected above 3% versus the initial 2%; and MA is approaching breakeven this year. Adjusted SG&A also beat consensus. These are real positives, but Medicare included approximately $160 million of favorable prior-year settlements, and CNC recorded no 2026 MA premium deficiency reserve after establishing $389 million by 2Q25. Commercial and Medicare are carrying more of the near-term recovery, but the quarter is not a clean run rate.
Better Medicaid rates were absorbed by worse attrition
Medicaid was stable, not weak. Its 93.9% 2Q26 HBR improved 100 basis points year over year and was in line with management’s forecast. The composite rate outlook increased to approximately 5.0% from 4.5%, modestly above the mid-4% fundamental trend. However, expected year-end membership attrition worsened to 8%–9% from approximately 6%. Management therefore held the incremental 50 basis points of rate favorability against the acuity effect of losing more members, leaving the full-year HBR outlook around 93.5%. That is a reasonable forecast posture, but it also means better rates did not translate to visible margin upside.
Source: Centene.
That unchanged HBR matters because Medicaid remains CNC’s largest identified long-term earnings lever. The current 93.5% outlook is roughly 350 basis points above the approximately 90% normalization marker used at the December 2024 Investor Day, where management associated the gap with $1.60–$2.00 of adjusted EPS opportunity. That sensitivity is stale and predates the 2025 earnings collapse, but it’s still useful for understanding the scale. Management now expects OB3-related eligibility pressure to mute the recovery through part of 2027, with acceleration more likely in the second half as rates catch up.
Membership mix adds to the timing risk. Expansion members were approximately 19% of the Medicaid book in 2Q and are expected to be about 18% at year-end. Management cited external estimates suggesting 25%–40% of that cohort could roll off over 2027–2029, equivalent to roughly 4.5%–7.2% of total membership using the expected year-end mix. Peers show the same rate-versus-cost problem: ELV kept its approximately negative 1.75% Medicaid margin outlook despite better rates, while MOH still expects 4% rates against 5% trend. The sector appears closer to stabilization than normalization.
The Street agrees on little beyond 2026
Consensus has adjusted accordingly. FY26 EPS increased to $4.89 on August 16 from $3.52 on July 27, while FY27 rose to $5.32 from $4.48. The current FY26 range is narrow at $4.80–$5.09 across 20 analysts; the FY27 range is much wider at $4.61–$6.25 across 21. Reported-base growth from the FY26 average is only 8.8%, but subtracting management’s $0.50 nonrecurring item from the current consensus creates a simple $4.39 normalized reference and raises implied FY27 growth to 21.2%. That simple normalization shows why the 2027 debate remains open.
Source: Koyfin; Graver Research calculations.
The stock has not rejected the print, but it has not fully reflected the estimate reset either. CNC rose 5.3% from July 27 through August 14, roughly matching the S&P 500’s 5.0% gain and beating XLV’s 2.4%, while FY27 consensus increased 18.8%. The implied FY27 P/E fell to 12.7x from 14.3x. On the separate NTM measure, CNC trades at 14.4x versus a 13.2x 10-year median, while its relative multiple to the S&P 500 is in line with history. Valuation is not demanding on the new FY27 number, but it is no longer distressed enough to make the timing of Medicaid recovery irrelevant.
What matters from here
The next tests are more specific than another quarterly EPS beat. Medicaid HBR needs to improve from the roughly 93.5% path as the July 1 rate cohort matures, even if membership reaches the 8%–9% attrition range. January 2027 rates must recognize current acuity and OB3, while the Marketplace risk-adjustment accrual needs to hold as more claims data arrive. PDP margin also needs to remain above 3% without another prior-year settlement. Management’s 2026-to-2027 bridge must then show how recurring gains offset the $0.50 that falls away.
CNC has earned a higher 2026 base and more benefit of the doubt on execution. It has not earned a straight-line extrapolation into normalized earnings. A Medicaid HBR below the current path, stronger January rate support and a clean recurring bridge would strengthen the case. More attrition-driven acuity pressure or a reversal in Marketplace risk adjustment would weaken it. For now, 2026 is largely settled. Whether rates can finally convert into Medicaid margin remains the thesis-defining question.